A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Patients with mantle cell lymphoma (MCL) that has relapsed (come back) or refractory
(progressed on treatment) will receive ixazomib and ibrutinib.
Ibrutinib has been approved by the Food and Drug Administration (FDA) as treatment for
patients with mantle cell lymphoma who have received at least one prior therapy.
Ixazomib is in a class of medications called proteasome inhibitors. Cancer cells depend on
proteasome to provide this protein metabolism (turnover) function to regulate their growth
and survival. Ixazomib disrupts a cancer cells' ability to survive by blocking the proteasome
and disrupting protein metabolism. This may help to slow down the growth of cancer or may
cause cancer cells to die.
The purpose of this study is to see whether the addition of ixazomib to ibrutinib
chemotherapy is effective in treating people who have relapsed or refractory MCL and to
examine the side effects associated with ixazomib in combination with ibrutinib.